University of Pennsylvania Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma
Condition: Renal Cell Carcinoma Interventions: Drug: Pembrolizumab infusion; Drug: Lenvatinib tablet Sponsors: Abramson Cancer Center of the University of Pennsylvania; Merck Sharp & Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 17, 2023 Category: Research Source Type: clinical trials
